Financial Disclosure

Dar Global Revenue Jumps 66% to $258M as GDV Hits $23bn

Riyadh – September 30, 2026 -- Dar Global, the London-listed luxury developer, posted a 66% revenue increase to US$258.0 million for the six months ended June 30, 2026, up from US$155.4 million in HY 2025.

Net profit more than doubles as margins widen across the portfolio

Gross profit climbed 85% to US$87.7 million, lifting margins to 34% from 31% a year earlier. EBITDA rose 73% to US$46.3 million, while net profit surged 149% to US$30.4 million from US$12.2 million, driven by revenue recognition on The Astera, Interiors by Aston Martin, and Neptune, Interiors by Mouawad.

Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Astrocyte Raises $9.5M Series B as Concussion Drug Trial Completes Enrollment

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

DeepWork Capital leads financing with four new investors joining the round

The Series B was led by DeepWork Capital, with continued backing from existing investors and new participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures. Jackson Streeter, M.D., Venture Partner at DeepWork Capital, said the firm has been impressed by the consistency of Astrocyte's science and the progress of its clinical programs.

Kenon to Pay $450M for 25% Stake in US District Energy Firm Vicinity

Singapore – – September 30, 2026 -- Kenon Holdings Ltd. has agreed to acquire a 25% equity interest in Vicinity District Energy for approximately $450 million, as part of a broader transaction valuing the company at $2.92 billion.

Antin Infrastructure Partners exits majority stake in $2.92 billion deal

The current owner, an entity related to Antin Infrastructure Partners, is selling a majority interest in Vicinity to a buyer jointly owned by Kenon and funds managed by Harrison Street Asset Management (HSAM). Under the Equity Purchase Agreement, the buyer will acquire between approximately 60% and 100% of Vicinity Holding Company. A consortium of lenders has committed non-recourse debt financing of up to $1.4 billion to fund part of the purchase price and future growth capital expenditures.

Smart Shooter Wins JIATF-401 Contract Worth Up to $150M for Counter-Drone Systems

United States – – September 30, 2026 -- Smart Shooter has secured a new contract from the U.S. Joint Interagency Task Force 401 (JIATF-401) under a framework valued at up to $150 million for future delivery orders, expanding the company's footprint in the U.S. counter-drone market.

Contract Supports Domestic Shield Program Against Drone Threats

The award backs JIATF-401's Domestic Shield Program and related global missions, covering force protection, base defense, and counter-UAS requirements both domestically and overseas. Scope includes hardware, software updates, training, and support services, with the volume and timing of future orders set through individual delivery orders.

EQT Foundation Funds €1M for 11 Brain Drug-Delivery Projects

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

Clarenta Group Acquires Majority Stake in Paris-Based L2D

London – September 30, 2026 -- Clarenta Group has taken a majority stake in Leads To Development (L2D), a Paris-based preclinical and regulatory consultancy, expanding its reach into early-stage drug development ahead of first-in-human trials.

Clarenta adds non-clinical and manufacturing expertise to its clinical development platform

L2D specializes in defining development pathways, assessing preclinical evidence, troubleshooting manufacturing processes, and building regulatory strategies for biotech and pharmaceutical sponsors. The addition connects this early-stage scientific work directly to Clarenta's existing Early Phase Unit and clinical consulting capabilities.

Norge Mining Secures $125M GEM Facility Tied to Future Listing

London – – September 30, 2026 -- Norge Mining Limited has entered a strategic partnership with GEM Global Yield LLC SCS, part of the $3.4 billion alternative investment group Global Emerging Markets, securing a share subscription facility of up to $125 million that activates only once the company completes a public listing.

GEM commits $125 million facility contingent on Norge Mining's stock market debut

The facility is designed to form part of a broader funding strategy as Norge Mining works to advance both upstream and downstream projects toward Final Investment Decisions. More than $100 million has already been invested in the company's development, covering exploration, resource definition and technical studies, and its upstream Pre-Feasibility Study has now been completed.

California GDP Grows 3.7% as State Unemployment Hits 5.1%, Highest in U.S.

Los Angeles – September 30, 2026 -- California's economy expanded at an annualized 3.7% rate in the first quarter of 2026, nearly double the 2.1% national growth rate, even as the state's unemployment rate climbed to 5.1% in August, the highest of any U.S. state, according to the UCLA Anderson Forecast's September 2026 outlook.

California outpaces every state but Washington in growth while shedding jobs by one measure

Over the year ending in the first quarter, California GDP grew 3.3% versus 2.7% nationally. Payroll employment rose by 138,500 jobs over the 12 months through August, but a separate household survey showed 246,700 fewer Californians employed and a 351,100 drop in the labor force over the same period. The state's unemployment rate has stayed above 5% for 31 consecutive months.

SWI Group Reports €4.4B Assets, Pivots to AI Compute Platform

Singapore – September 30, 2026 -- SWI Capital Holding Ltd. (Euronext Amsterdam: SWICH) reported €4.4 billion in total assets and €2.3 billion in Adjusted NAV for the six months ended June 30, 2026, a 53% increase from December 31, 2025, as the group accelerates its pivot from a diversified holding company into a global AI infrastructure and compute platform.

Profit surges on Genesis Digital Assets stake

Profit for the period reached €631.6 million, driven primarily by the value recognized on SWI Group's investment in Genesis Digital Assets, since rebranded SWI Digital. The interim report was reviewed by Deloitte.